Highlights on The AntimutagenecityImpact of E. schimperiana and E. balsamifera with Respect to Their Toxicity

Document Type : Original Article

Authors

1 Therapeutic Chemistry Department, National Research Centre

2 Therapeutic Chemistry Dept.

3 Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Egypt.

4 Department of Genetics and Cytology, National Research Centre, Cairo, Egypt.

5 Department of Genetics and Cytology, National Research Centre, Egypt.

6 Chemistry of Natural Compounds Department, National Research Centre, Egypt. Abstract

Abstract

Medicinal plant is considered  a double edged sword that could be beneficial or toxic to people or animals. Accordingly, this study is concerned with vitro and vivo evaluation ofEuphorbiaschimperiana and Euphorbia balsamiferatoxicity in rats. A comparison study was carried out between both extracts on THLE2 and WI38 cell lines. Furthermore, the anti-inflammatory and the anti-mutagenicity influence of both target plants were studied in rats administrated monoiodoacetate. The study was supported by biochemical and the histological examinations of key organs. Methanol extract of  E.schimperiana and E. Balsamifera displayed IC50 values of 30.6±1.96 and 88.7±5.67 respectively on WI38 cell lines. The chloroform fraction of E. schimperiana showed the greatest safety profile  with IC50 value of 72±3.74 while  petroleum ether fraction of  E. balsamifera displayed the maximum safety profile among the other fractions with IC50 value of 56 ±3.74 onTHLE2  cells. Male Wistar rats administered orally 2.5 mg/kg of methanol extract did not show any fatalities or ill effects. The daily dose of the two extracts demonstrated a substantial dose dependent decrease in the percentage of MNPEs and chromosomal abnormalities; due to mono-iodoacetate administration, suggesting the valuable role of  the target plants.

Keywords

Main Subjects


Volume 66, Issue 13 - Serial Number 13
Special Issue: Applied Chemistry for Greener Life and Sustainability
December 2023
Pages 1141-1153
  • Receive Date: 11 April 2023
  • Revise Date: 20 May 2023
  • Accept Date: 22 May 2023